Cite

    B Fautrel et al.. “Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison.” RMD open, vol. 6, no. 1, 2020, p. . http://access.bl.uk/ark:/81055/vdc_100137793524.0x000001